Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Membranoproliferative Glomerulonephritis (MPGN) has a higher frequency in Pakistan as compared to the Western World. It is also observed that incidence of reported cases of MPGN have been increasing in our center over last 3 to 4 years, while the presentation is diversified from slowly progressive disease, i.e. with microscopic hematuria and non-nephrotic proteinuria to nephrotic syndrome and more severe presentations like rapidly progressive glomerulonephritis (RPGN). This study aims to focus on the patterns of MPGN in our population along with its short-term clinicopathological features and outcomes.
The major objective of this research is to study the clinicopathological features and outcomes of patients diagnosed with MPGN, enrolled in the desired duration of study.
It was a prospective cohort study conducted between December, 2020 till August, 2022 at Sindh Institute of Urology and Transplantation (SIUT) among the local residents.
The participants of this study were recruited from nephrotic clinic and in-patients. All the specimens for renal biopsy were examined for immunofluorescence and light microscopy. Data were retrieved by reviewing case notes of the patients after prior approval from the research and ethical committee using a pre-designed proforma for every patient. The proforma included all the demographic details, along with patient’s major signs and symptoms, laboratory findings such as CBC, urea, creatinine, electrolytes, serum albumin, 24 hours urine for protein excretion and/or spot urine for protein creatinine ratio, presence or absence of hematuria and proteinuria, and serological markers like complements (C3, C4), ANA, Anti ds DNA, Hepatitis B surface antigen vii(HbsAg), Anti hepatitis C antibody (anti-HCV) and immunofixation. Patients meeting the designed inclusion criteria were enrolled in this study after obtaining the consent.
A total of 87 patients were enrolled in the study. The mean age was 44.35 ± 14.3 years, and 67% were female. The mean follow-up duration was 6 months after biopsy. Crescents were observed in 50.57% (44/87) of patients, with cellular crescents being the most common (72.72%). Immunoglobulin deposition (65.5%) was more frequent than complement deposition (54%), with IgG as the main contributor. C3 deposition in isolation was seen in 17 patients (19.5%); however, limited access to electron microscopy hindered the confirmation of C3GN. Immunosuppression with steroids and cyclophosphamide was administered to 70% of patients.
Patients were divided into two groups: those requiring dialysis (13) and those managed conservatively (74). Outcomes were assessed based on reduction in proteinuria and changes in eGFR. Among dialysis patients, complete remission was seen in 37.5%, partial in 25%, and no remission in 37.5%. Regarding eGFR, 12.5% showed complete recovery (eGFR > 60 ml/min/1.73m²), 25% recovered partially (eGFR 45–59), and 62.5% were classified as CKD (eGFR < 45). Among non-dialysis patients, 53.84% achieved complete remission, 19.23% partial, and 26.92% had no remission. Complete renal recovery was seen in 69.23%, partial in 17.37%, while 13.46% were labelled as CKD due to persistent eGFR < 45 ml/min/1.73m².
MPGN remains a common glomerular diagnosis in this setting. Nearly half of the patients had crescentic involvement, and many required dialysis at presentation. As most patients had immune-complex–mediated MPGN likely triggered by subclinical infections, renal improvement may have occurred spontaneously, aided by the resolution of the underlying immune response.
